Parallel Advisors’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.31K Hold
97
﹤0.01% 3321
2025
Q4
$2.69K Hold
97
﹤0.01% 3053
2025
Q3
$2.35K Hold
97
﹤0.01% 3006
2025
Q2
$1.65K Sell
97
-18
-16% -$313 ﹤0.01% 3086
2025
Q1
$2.41K Buy
115
+15
+15% +$393 ﹤0.01% 2922
2024
Q4
$2.48K Buy
100
+13
+15% +$332 ﹤0.01% 2896
2024
Q3
$2.13K Buy
87
+1
+1% +$26 ﹤0.01% 2873
2024
Q2
$2.02K Hold
86
﹤0.01% 2808
2024
Q1
$2.84K Hold
86
﹤0.01% 2714
2023
Q4
$2.34K Sell
86
-227
-73% -$5.64K ﹤0.01% 2754
2023
Q3
$7.53K Buy
313
+300
+2,308% +$8.04K ﹤0.01% 2331
2023
Q2
$415 Sell
13
-44
-77% -$1.43K ﹤0.01% 3135
2023
Q1
$1.75K Sell
57
-376
-87% -$14.8K ﹤0.01% 2812
2022
Q4
$16.9K Buy
433
+395
+1,039% +$17.7K ﹤0.01% 1783
2022
Q3
$2K Buy
38
+14
+58% +$799 ﹤0.01% 2592
2022
Q2
$1K Sell
24
-21
-47% -$835 ﹤0.01% 2704
2022
Q1
$3K Sell
45
-62
-58% -$4.07K ﹤0.01% 2441
2021
Q4
$9K Buy
107
+88
+463% +$7.54K ﹤0.01% 2141
2021
Q3
$2K Buy
19
+9
+90% +$904 ﹤0.01% 2650
2021
Q2
$1K Hold
10
﹤0.01% 2695
2021
Q1
$1K Hold
10
﹤0.01% 2581
2020
Q4
$1K Buy
+10
New +$492 ﹤0.01% 2398

Other funds holding BEAM

Parallel Advisors's BEAM Position: Q1 2026 in Review

Parallel Advisors held its Beam Therapeutics (BEAM) position steady in Q1 2026 at 97 shares worth $2.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3321.

Parallel Advisors first reported a position in BEAM in Q4 2020 and has held it in 22 quarters since. The position peaked at $16.9K in Q4 2022. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Parallel Advisors held 97 shares of Beam Therapeutics worth $2.31K as of Q1 2026.
  • Parallel Advisors left its Beam Therapeutics share count unchanged in Q1 2026.
  • Beam Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3321 holding.
  • Parallel Advisors first reported a position in Beam Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Parallel Advisors's Beam Therapeutics position peaked at $16.9K in Q4 2022.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.